HARBIN, China, Nov. 11 /PRNewswire-Asia-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), today announced that it will
conduct a conference call at 8:00 a.m. Eastern Standard Time (EST) on Tuesday,
November 17, 2009, to discuss its third quarter 2009 financial results.
Joining Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical, Inc.,
will be Stanley Hao, Chief Financial Officer. The Company plans to issue an
earnings announcement prior to the call.
To participate in the live conference call, please dial the following
number five to ten minutes prior to the scheduled conference call time: 1 888
419 5570. International callers should dial +1 617 896 9871. The Conference ID
for this call is 814 194 70.
If you are unable to participate in the call at this time, a replay will
be available for fourteen days starting on Tuesday, November 17, 2009 at 10:00
a.m. Eastern Standard Time. To access the replay, dial 888 286 8010,
international callers dial 617 801 6888. The Conference Replay Passcode is 254
153 02.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang
Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang
Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue
source. For more information, visit http://www.skyonemedical.com.
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
the change of independent directors. Actual results could differ materially
from the expectations reflected in such forward-looking statements as a result
of a variety of factors, including the risks associated with the effect of
changing economic conditions in The People's Republic of China, variations in
cash flow, reliance on collaborative retail partners and on new product
development, variations in new product development, risks associated with
rapid technological change, and the potential of introduced or undetected
flaws and defects in products, and other risk factors detailed in reports
filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Yu-Bo Hao, CFO
Tel: +86-451-5399-4069
Email: china_sky_one@yahoo.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Website: http://www.ccgirasia.com